Merck & Company, Inc. vs Gilead Sciences, Inc.
A head-to-head of Merck & Company, Inc. (MRK) and Gilead Sciences, Inc. (GILD) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | MRK | GILD |
|---|---|---|
| Market Cap | $314.90B | $166.72B |
| P/E (TTM) | 35.92 | 18.29 |
| Forward P/E | 13.20 | 13.83 |
| P/S | 4.40 | 5.61 |
| P/B | 9.93 | 7.12 |
| EV/EBITDA | 17.18 | 12.15 |
| Dividend Yield | 1.80% | 2.42% |
| Profit Margin | 13.59% | 30.99% |
| Gross Margin | 74.80% | 78.83% |
| Operating Margin | 34.01% | 39.74% |
| Revenue Growth (YoY) | +4.87% | +4.39% |
| FCF Yield | 4.88% | 6.13% |
| Debt / Equity | 106.94 | 94.64 |
| Current Ratio | 1.30 | 1.97 |
Which is better: Merck & Company, Inc. or Gilead Sciences, Inc.?
- ✓Larger by market cap: Merck & Company, Inc.
- ✓Cheaper valuation (lower P/E): Gilead Sciences, Inc.
- ✓Higher dividend yield: Gilead Sciences, Inc.
- ✓More profitable (net margin): Gilead Sciences, Inc.
- ✓Faster revenue growth: Merck & Company, Inc.
- ✓Higher free-cash-flow yield: Gilead Sciences, Inc.
Across 13 available metrics, Gilead Sciences, Inc. leads 10–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.